LoValTech is a deeptech startup created in January 2022 to relay the academic research of the University of Tours and INRAE to bring the first vaccine candidate to its clinical phases. Winner of the i-Lab and France 2030 competitions, the company develops next-generation vaccines. These vaccNasal proteins are able to better protect all populations against infectious diseases, such as COVID-19, by inducing a dual mucosal and systemic immune response, which not only protects against severe forms but also blocks transmission of the virus.